Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ATB-720 is an antisense oligonucleotide (ASO) therapeutic candidate under development by Autotelic Bio. It is characterized as a first-in-class immune modulator designed for the treatment of inflammatory dermatological conditions, specifically atopic dermatitis and psoriasis. Currently in the discovery stage, ATB-720 utilizes RNA-targeting technology to modulate immune pathways associated with the pathogenesis of these skin diseases. As an RNA-based therapy, it aims to provide a targeted approach to immune regulation, though its specific molecular target has not been publicly disclosed by the developer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ATB-720.